Co-operativity in agonist binding at the D2 dopamine receptor: Evidence from agonist dissociation kinetics

Journal of Neurochemistry

Volumn 112, Issue 6, 2010, Pages 1442-1453

  Kara, Elodie ^a   Lin, Hong ^a   Strange, Philip G ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

Agonist binding; Co operativity; D2 dopamine receptor; Ligand dissociation; Oligomers

Indexed keywords

ARIPIPRAZOLE; BUTACLAMOL; DOPAMINE; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; GUANOSINE TRIPHOSPHATE; HALOPERIDOL; PROPYLNORAPOMORPHINE; SODIUM ION;

ANIMAL CELL; ARTICLE; BINDING SITE; CHO CELL; CONTROLLED STUDY; DISSOCIATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; APOMORPHINE; BRAIN; CHO CELLS; CRICETINAE; CRICETULUS; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; PROTEIN BINDING; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D2; TISSUE DISTRIBUTION; TRITIUM;

EID: 77349094966     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2009.06554.x     Document Type: Article

References (46)

1. Abbott A. J. Nelsestuen G. L. (1988) The collisional limit: an important consideration for membrane-associated enzymes and receptors. FASEB J. 2, 2858 2866.
2. Armstrong D. Strange P. G. (2001) Dopamine D2 receptor dimer formation: evidence from ligand binding. J. Biol. Chem. 276, 22621 22629.
3. Bulenger S., Marullo S. Bouvier M. (2005) Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol. Sci. 26, 131 137.
4. Carriba P., Ortiz O., Patkar K. et al. (2007) Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology 32, 2249 2259.
5. Chatterjee T. K., Scott C. E., Vazquez D. M. Bhatnagar R. K. (1988) Interaction of [3H]spiperone with rat striatal dopamine D-2 receptors: kinetic evidence for antagonist-induced formation of ternary complex. Mol. Pharmacol. 33, 402 413.
6. Cheng Y. Prusoff W. H. (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099 3108.
7. Cohen F. R., Lazareno S. Birdsall N. J. (1996) The effects of saponin on the binding and functional properties of the human adenosine A1 receptor. Br. J. Pharmacol. 117, 1521 1529.
8. Cox M. A., Jenh C. H., Gonsiorek W., Fine J., Narula S. K., Zavodny P. J. Hipkin R. W. (2001) Human interferon-inducible 10-kDa protein and human interferon-inducible T cell alpha chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states. Mol. Pharmacol. 59, 707 715.
9. De Lean A., Stadel J. M. Lefkowitz R. J. (1980) A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J. Biol. Chem. 255, 7108 7117.
10. Fotiadis D., Liang Y., Filipek S., Saperstein D. A., Engel A. Palczewski K. (2003) Atomic-force microscopy: rhodopsin dimers in native disc membranes. Nature 421, 127 128.
11. Franco R., Casado V., Ciruela F., Mallol J., Lluis C. Canela E. I. (1996) The cluster-arranged cooperative model: a model that accounts for the kinetics of binding to A1 adenosine receptors. Biochemistry 35, 3007 3015.
12. Gazi L., Lopez-Gimenez J. F., Rudiger M. P. Strange P. G. (2003) Constitutive oligomerization of human D2 dopamine receptors expressed in Spodoptera frugiperda 9 (Sf9) and in HEK293 cells. Analysis using co-immunoprecipitation and time-resolved fluorescence resonance energy transfer. Eur. J. Biochem. 270, 3928 3938.
13. Gettys T. W., Sheriff-Carter K., Moomaw J., Taylor I. L. Raymond J. R. (1994) Characterization and use of crude alpha-subunit preparations for quantitative immunoblotting of G proteins. Anal. Biochem. 220, 82 91.
14. Hall H., Wedel I., Halldin C., Kopp J. Farde L. (1990) Comparison of the in vitro receptor binding properties of N-[3H]methylspiperone and [3H]raclopride to rat and human brain membranes. J. Neurochem. 55, 2048 2057.
15. Hayes G., Biden T. J., Selbie L. A. Shine J. (1992) Structural subtypes of the dopamine D2 receptor are functionally distinct: expression of the cloned D2A and D2B subtypes in a heterologous cell line. Mol. Endocrinol. 6, 920 926.
16. Hern J., Browning C., Baig A. Birdsall N. (2004) Ligand induced agonist dissociation from human adenosine A1 receptor-G protein complexes. Proceedings of the British Pharmacological Society http://www.pa2online.org/ Vol1Issue4abst053P.html.
17. Hirschberg B. T. Schimerlik M. I. (1994) A kinetic model for oxotremorine M binding to recombinant porcine m2 muscarinic receptors expressed in Chinese hamster ovary cells. J. Biol. Chem. 269, 26127 26135.
18. Hoare S. R. Strange P. G. (1996) Regulation of D2 dopamine receptors by amiloride and amiloride analogs. Mol. Pharmacol. 50, 1295 1308.
19. Kobilka B. Schertler G. F. (2008) New G-protein-coupled receptor crystal structures: insights and limitations. Trends Pharmacol. Sci. 29, 79 83.
20. Korner M., Gilon C. Schramm M. (1982) Locking of hormone in the beta-adrenergic receptor by attack on a sulfhydryl in an associated component. J. Biol. Chem. 257, 3389 3396.
21. Lefkowitz R. J., Cotecchia S., Samama P. Costa T. (1993) Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol. Sci. 14, 303 307.
22. Limbird L. E. Lefkowitz R. J. (1976) Negative cooperativity among beta-adrenergic receptors in frog erythrocyte membranes. J. Biol. Chem. 251, 5007 5014.
23. Lin H., Saisch S. G. Strange P. G. (2006) Assays for enhanced activity of low efficacy partial agonists at the D(2) dopamine receptor. Br. J. Pharmacol. 149, 291 299.
24. Lowry O. H., Rosebrough N. J., Farr A. L. Randall R. J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265 275.
25. Ma A. W., Redka D. S., Pisterzi L. F., Angers S. Wells J. W. (2007) Recovery of oligomers and cooperativity when monomers of the M2 muscarinic cholinergic receptor are reconstituted into phospholipid vesicles. Biochemistry 46, 7907 7927.
26. Maggio R., Vogel Z. Wess J. (1993) Coexpression studies with mutant muscarinic/adrenergic receptors provide evidence for intermolecular "cross-talk" between G-protein-linked receptors. Proc. Natl Acad. Sci. USA 90, 3103 3107.
27. Makman M. H., Dvorkin B. Klein P. N. (1982) Sodium ion modulates D2 receptor characteristics of dopamine agonist and antagonist binding sites in striatum and retina. Proc. Natl Acad. Sci. USA 79, 4212 4216.
28. Neve K. A., Cox B. A., Henningsen R. A., Spanoyannis A. Neve R. L. (1991) Pivotal role for aspartate-80 in the regulation of dopamine D2 receptor affinity for drugs and inhibition of adenylyl cyclase. Mol. Pharmacol. 39, 733 739.
29. Park P. S., Sum C. S., Pawagi A. B. Wells J. W. (2002) Cooperativity and oligomeric status of cardiac muscarinic cholinergic receptors. Biochemistry 41, 5588 5604.
30. Price M. R., Baillie G. L., Thomas A. et al. (2005) Allosteric modulation of the cannabinoid CB1 receptor. Mol. Pharmacol. 68, 1484 1495.
31. Rashid A. J., So C. H., Kong M. M., Furtak T., El-Ghundi M., Cheng R., O'Dowd B. F. George S. R. (2007) D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc. Natl Acad. Sci. USA 104, 654 659.
32. Raymond J. R., Olsen C. L. Gettys T. W. (1993) Cell-specific physical and functional coupling of human 5-HT1A receptors to inhibitory G protein alpha-subunits and lack of coupling to Gs alpha. Biochemistry 32, 11064 11073.
33. Rios C. D., Jordan B. A., Gomes I. Devi L. A. (2001) G-protein-coupled receptor dimerization: Modulation of receptor function. Pharmacol. Ther. 92, 71 87. (Pubitemid 34251127)
34. Roberts D. J. Strange P. G. (2005) Mechanisms of inverse agonist action at D2 dopamine receptors. Br. J. Pharmacol. 145, 34 42.
35. Rozenfeld R. Devi L. A. (2007) Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers. FASEB J. 21, 2455 2465.
36. Severne Y., Ijzerman A., Nerme V., Timmerman H. Vauquelin G. (1987) Shallow agonist competition binding curves for beta-adrenergic receptors: The role of tight agonist binding. Mol. Pharmacol. 31, 69 73.
37. Sibley D. R., De Lean A. Creese I. (1982) Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor. J. Biol. Chem. 257, 6351 6361.
38. Springael J. Y., Le Minh P. N., Urizar E., Costagliola S., Vassart G. Parmentier M. (2006) Allosteric modulation of binding properties between units of chemokine receptor homo- and hetero-oligomers. Mol. Pharmacol. 69, 1652 1661.
39. Strange P. G. (1996) The energetics of ligand binding at catecholamine receptors. Trends Pharmacol. Sci. 17, 238 244.
40. Strange P. G. (2001) Antipsychotic drugs: Importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol. Rev. 53, 119 133.
41. Undie A. S. Friedman E. (1990) Stimulation of a dopamine D1 receptor enhances inositol phosphates formation in rat brain. J. Pharmacol. Exp. Ther. 253, 987 992.
42. Vivo M., Lin H. Strange P. G. (2006) Investigation of cooperativity in the binding of ligands to the D(2) dopamine receptor. Mol. Pharmacol. 69, 226 235.
43. Weiss J. M., Morgan P. H., Lutz M. W. Kenakin T. P. (1996) The cubic ternary complex receptor-occupancy model. III. resurrecting efficacy. J. Theor. Biol. 181, 381 397.
44. Whorton M. R., Bokoch M. P., Rasmussen S. G., Huang B., Zare R. N., Kobilka B. Sunahara R. K. (2007) A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein. Proc. Natl Acad. Sci. USA 104, 7682 7687.
45. Whorton M. R., Jastrzebska B., Park P. S., Fotiadis D., Engel A., Palczewski K. Sunahara R. K. (2008) Efficient coupling of transducin to monomeric rhodopsin in a phospholipid bilayer. J. Biol. Chem. 283, 4387 4394.
46. Wong H. M., Sole M. J. Wells J. W. (1986) Assessment of mechanistic proposals for the binding of agonists to cardiac muscarinic receptors. Biochemistry 25, 6995 7008.